Menopause Management

Disclaimer: > [!WARNING] Medical Disclaimer: This content is for educational and informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for diagnosis and treatment. Medical guidelines and best practices change rapidly; users should verify information with current local protocols.

1. Clinical Overview

Menopause is defined retrospectively as 12 months of amenorrhoea due to permanent cessation of ovarian function, specifically follicular depletion. The average age in the UK is 51 years (range 45-55). [1,2]

Perimenopause (climacteric) is the transition period characterized by vasomotor symptoms, menstrual irregularity, and fluctuating hormone levels, typically beginning 2-8 years before the final menstrual period. [3]

Premature Ovarian Insufficiency (POI), previously termed "premature menopause," occurs before age 40 and affects approximately 1-2% of women. It has distinct management implications requiring HRT until the natural age of menopause for cardiovascular and bone protection. [4,5]

---

2. Visual Summary Panel

Image Integration Plan

[!NOTE] Image Generation Status: Diagrams illustrating the 'Estrogen Withdrawal' cascade and HRT decision algorithm are queued.

HRT Prescribing Algorithm - Golden Rules

1. Uterus Present? You MUST give Progesterone (minimum 12 days/month) to prevent endometrial hyperplasia/cancer.
2. Last Menstrual Period (LMP) less than 12 months? Give Sequential/Cyclical HRT (Daily Oestrogen + Progesterone 12-14 days = withdrawal bleed).
3. LMP > 12 months? Give Continuous Combined HRT (Daily Oestrogen + Daily Progesterone = amenorrhoea).
4. No Uterus (post-hysterectomy)? Give Oestrogen Only (unopposed oestrogen is safe and avoids unnecessary progesterone side effects).
5. VTE/obesity/migraine risk? Transdermal route (patch, gel, spray) is mandatory - no first-pass hepatic metabolism.

---

3. Epidemiology

Age Distribution

• Natural Menopause: Mean age 51 years (45-55 years in 95% of women). [1]
• Early Menopause: 40-45 years (affects ~5% of women).
• Premature Ovarian Insufficiency (POI): less than 40 years (prevalence 1-2%). [4,5]
• Surgical Menopause: Following bilateral oophorectomy - often causes severe acute symptoms due to abrupt hormone withdrawal.

Global Variation

• Genetics account for ~50% of variation in age at menopause.
• Smoking advances menopause by ~1-2 years. [6]
• Higher socioeconomic status associated with later menopause.
• Ethnicity variations: African-American women enter menopause ~2 years earlier than Caucasian women on average.

Prevalence of Symptoms

• Vasomotor symptoms: 75-80% of women experience hot flushes/night sweats. [3,7]
• Duration: Median 7.4 years; 10% experience symptoms >20 years.
• Genitourinary Syndrome of Menopause (GSM): ~50% of postmenopausal women, but often under-reported. [8]
• Psychological symptoms: Mood disturbance/anxiety in 40-50%, but causality debated.

---

4. Pathophysiology

Ovarian Follicular Depletion

Women are born with ~1-2 million primordial follicles. By puberty, ~300,000-400,000 remain. Through atresia and ovulation, follicles deplete throughout reproductive life. Menopause occurs when follicle numbers fall below ~1,000. [1,2]

Hormonal Changes

Key Sequence:

1. Early Perimenopause: Declining inhibin B → FSH rises → follicular recruitment increases → shorter cycles, normal/high oestradiol.
2. Late Perimenopause: Fewer follicles respond → erratic oestradiol (high/low swings) → chaotic cycles, anovulation.
3. Postmenopause: Oestradiol falls to less than 100 pmol/L → FSH persistently elevated (>30 IU/L) → LH also elevated.

Residual Hormone Production:

• Ovarian stroma continues producing androgens (androstenedione, testosterone).
• Peripheral aromatization in adipose tissue converts androgens to oestrone (weaker oestrogen).
• Postmenopausal women are NOT completely oestrogen-deficient, but levels are insufficient to prevent symptoms/bone loss.

Consequences of Oestrogen Deficiency

Vasomotor Symptoms

• Narrowing of the thermoneutral zone in the hypothalamus.
• Small core temperature fluctuations trigger inappropriate heat dissipation responses (peripheral vasodilation, sweating). [7]
• Exact mechanism incompletely understood; likely involves serotonergic, noradrenergic pathways.

Bone Loss

• Oestrogen inhibits osteoclast activity via multiple pathways (OPG/RANKL system, cytokine modulation).
• Oestrogen deficiency → uncoupling of bone remodeling → net bone loss (1-2% annually in first 5-10 years). [9]
• Peak bone loss occurs in early postmenopause; cumulative loss ~30% trabecular, 10% cortical bone over lifetime.

Urogenital Atrophy

• Oestrogen-dependent tissues (vagina, urethra, bladder trigone) undergo epithelial thinning.
• Loss of glycogen → reduced lactobacilli → vaginal pH rises (4.5 → 6-7) → dysbiosis, infection risk.
• Clinical manifestations: dryness, dyspareunia, urinary frequency/urgency, recurrent UTIs (Genitourinary Syndrome of Menopause). [8]

Cardiovascular Changes

• Loss of cardioprotective effects of oestrogen (endothelial function, lipid profile, vascular tone).
• Accelerated atherosclerosis post-menopause (but HRT timing hypothesis applies - see Management). [10]

Cognitive and Psychological

• Role of oestrogen in cognition controversial.
• "Brain fog" commonly reported but objective cognitive decline not consistently demonstrated in healthy women.
• Depression/anxiety may relate to sleep disruption (night sweats), psychosocial factors, rather than direct hormone effect. [11]

---

5. Clinical Presentation

Menstrual Changes

• Early perimenopause: Shorter cycles (follicular phase shortening), heavier bleeding.
• Late perimenopause: Skipped cycles, prolonged amenorrhoea (>60 days), unpredictable heavy/light bleeding.
• Red flag: Any postmenopausal bleeding (>12 months amenorrhoea) requires urgent investigation for endometrial cancer.

Vasomotor Symptoms (VMS)

• Hot flushes: Sudden sensation of intense heat, flushing, tachycardia; lasts 1-5 minutes.
• Night sweats: Drenching sweats disrupting sleep (often most disabling symptom).
• Frequency: 1-2 to >20 episodes daily.
• Triggers: Spicy food, alcohol, stress, hot environments.
• Usually resolve gradually but can persist >10 years in 10% of women. [3,7]

Genitourinary Syndrome of Menopause (GSM)

Previously termed "vulvovaginal atrophy," now recognized as multi-system:

• Vaginal: Dryness, burning, dyspareunia, loss of lubrication.
• Urinary: Frequency, urgency, nocturia, dysuria, recurrent UTIs.
• Examination: Pale, dry, thin vaginal mucosa; loss of rugae; petechiae; pH >5.
• GSM is chronic and progressive - does NOT spontaneously resolve without treatment. [8]

Psychological and Cognitive

• Low mood, irritability, anxiety (causality uncertain - confounded by sleep disruption, life stressors).
• "Brain fog," poor concentration, memory lapses (subjective complaints common; objective testing inconsistent).
• Sleep disturbance (often secondary to night sweats).

Musculoskeletal

• Joint aches/"menopausal arthralgia" (mechanism unclear - inflammatory? oestrogen receptors in joints?).
• Accelerated muscle loss (sarcopenia).

Sexual Function

• Reduced libido (multifactorial: oestrogen, androgens, psychological, relationship factors).
• Dyspareunia (due to GSM).

---

6. Clinical Assessment

History

Menstrual History:

• Last menstrual period (LMP) - critical for HRT regimen choice.
• Pattern of bleeding (regular/irregular, heavy/light).
• Any postmenopausal bleeding (PMB) - requires urgent investigation.

Symptom Severity:

• Vasomotor symptoms (frequency, severity, impact on quality of life).
• Genitourinary symptoms (dryness, dyspareunia, urinary).
• Psychological symptoms (mood, sleep, cognition).

Past Medical/Surgical History:

• Hysterectomy ± oophorectomy status (determines HRT regimen).
• Cardiovascular disease, VTE, stroke (affects HRT suitability).
• Breast/endometrial cancer (contraindications to HRT).
• Migraine (affects route - transdermal preferred if migraine with aura).
• Liver disease (affects metabolism).

Family History:

• Breast/ovarian cancer (BRCA status if known).
• Premature menopause/POI.
• Osteoporosis, cardiovascular disease.

Medications:

• Current HRT or previous trials.
• Contraception (still needed if less than 50 and less than 12 months amenorrhoea, or less than 55 and less than 24 months amenorrhoea).

Lifestyle:

• Smoking (contraindication to oral HRT).
• BMI (>30 favours transdermal route).
• Alcohol intake (breast cancer risk factor).
• Exercise, calcium/vitamin D intake.

Examination

1. Blood Pressure: Essential before HRT initiation (HRT not recommended if uncontrolled hypertension).
2. BMI/Weight: Influences VTE risk and route choice.
3. Breast Examination: Ensure screening up to date (mammography 50-70 years UK).
4. Pelvic Examination (if indicated): Vaginal atrophy, cervical screening status.

---

7. Investigations

The Golden Rule: Diagnosis is Clinical in Women >45 Years

DO NOT routinely measure FSH/LH/Oestradiol in women >45 years with typical menopausal symptoms. [1,2,12]

Rationale:

• Hormone levels fluctuate wildly during perimenopause.
• A single FSH result cannot confirm/exclude menopause.
• Causes unnecessary medicalization and delay.

Indications for Hormone Testing

FSH Testing Recommended:

1. Women less than 40 years (suspected POI) - measure FSH on two occasions 4-6 weeks apart:
   • FSH >30 IU/L on two occasions = POI (also check oestradiol less than 100 pmol/L). [4,5]
2. Women 40-45 years with atypical symptoms or diagnostic uncertainty.
3. Women on combined oral contraceptive pill (COCP): Stop COCP or switch to progestogen-only for 6 weeks before testing (or measure on days 2-5 of pill-free week).

Additional Tests in POI/Early Menopause:

• Karyotype: Turner syndrome (45,XO), mosaicism.
• FMR1 gene: Fragile X premutation (CGG repeats 55-200).
• Autoimmune screen: Adrenal antibodies (Addison's), thyroid antibodies (Hashimoto's), anti-ovarian antibodies.
• Pelvic ultrasound: Ovarian volume, antral follicle count.

Investigations Before HRT Initiation

Mandatory:

• Blood pressure.

Recommended:

• BMI.
• Cervical screening up to date.
• Mammography up to date (if age 50-70 UK).

Consider (if risk factors):

• Lipid profile (CVD risk).
• HbA1c/fasting glucose (diabetes screening).
• DEXA scan (bone density if POI, early menopause, fracture risk factors). [9]
• Thrombophilia screen (NOT routine; only if personal/strong family history VTE).

Investigations for Postmenopausal Bleeding (PMB)

Red Flag - Urgent referral (2-week wait pathway):

• Transvaginal ultrasound: Endometrial thickness >4 mm requires endometrial biopsy.
• Hysteroscopy ± endometrial biopsy.
• Exclude endometrial cancer, hyperplasia, polyps.

---

8. Management

A. Non-Hormonal Treatments

Lifestyle Modifications

• Diet: Ensure adequate calcium (700-1000 mg/day) and vitamin D (10 mcg/day UK). [9]
• Weight-bearing exercise: 30 minutes daily (bone health, cardiovascular, weight management).
• Smoking cessation: Improves symptoms, bone health, reduces HRT risks.
• Reduce triggers: Spicy food, caffeine, alcohol for VMS.
• Vaginal moisturizers: Regular use (not just with intercourse) for GSM symptom relief.

Cognitive Behavioural Therapy (CBT)

• Evidence-based for VMS and mood disturbance.
• Reduces distress/impact of hot flushes (not frequency).
• Group or individual formats; online programs available. [13]

Pharmacological (Non-HRT)

For Vasomotor Symptoms:

1. SSRIs/SNRIs (off-label):

   • Venlafaxine 37.5-75 mg (most evidence) - reduces VMS ~50%.
   • Paroxetine, citalopram, escitalopram.
   • Side effects: Nausea, headache, sexual dysfunction.
   • Caution: Avoid in women on tamoxifen (enzyme interaction with paroxetine/fluoxetine).

2. Clonidine (alpha-2 agonist):

   • 50-75 mcg BD.
   • Modest efficacy (~20% reduction VMS).
   • Side effects: Dry mouth, drowsiness, constipation.

3. Gabapentin (off-label):

   • 300-900 mg daily.
   • Effective for VMS (comparable to venlafaxine).
   • Side effects: Sedation, dizziness.

For Genitourinary Syndrome:

• See "Local Oestrogen" section below.

For Sleep:

• Address night sweats (treat VMS).
• Sleep hygiene.
• Avoid benzodiazepines long-term.

For Bone Protection (if HRT declined/contraindicated):

• Bisphosphonates (alendronate 70 mg weekly).
• Denosumab, raloxifene (selective oestrogen receptor modulator - also reduces breast cancer risk).

---

B. Hormone Replacement Therapy (HRT)

HRT is the most effective treatment for menopausal symptoms and prevents osteoporotic fractures. [1,2,12,14]

1. Oestrogen Therapy

Types:

• Estradiol (17β-oestradiol - body-identical):
  • Oral: Estradiol valerate (Elleste Solo, Progynova) 1-2 mg.
  • Transdermal: Patches (Evorel, Estradot) 25-100 mcg; Gel (Oestrogel, Sandrena) 0.5-1.5 mg; Spray (Lenzetto).
• Conjugated equine oestrogens (CEE): Premarin 0.3-1.25 mg (used in WHI study - NOT body-identical).

Route Choice:

Transdermal is MANDATORY if:

• Personal history of VTE.
• Thrombophilia.
• BMI >30.
• Migraine with aura.
• Active smoker (though HRT generally avoided). [1,12]

2. Progesterone Therapy (for Endometrial Protection)

Regimens:

• Sequential/Cyclical: Progesterone 12-14 days per month → withdrawal bleed.
  • Use if: LMP less than 12 months (perimenopausal).
• Continuous Combined: Progesterone daily → amenorrhoea (after ~3-6 months).
  • Use if: LMP >12 months (postmenopausal).

Types:

1. Micronised Progesterone (Utrogestan):

   • 200 mg days 1-14 (sequential) or 100 mg daily (continuous).
   • Body-identical.
   • Lower breast cancer signal than synthetic progestogens. [15]
   • Can be taken vaginally if oral side effects.

2. Dydrogesterone (Femoston):

   • 10 mg days 1-14 (sequential) or 5 mg daily (continuous).
   • Synthetic but similar safety profile to micronised progesterone.

3. Levonorgestrel IUS (Mirena):

   • 20 mcg/day intrauterine.
   • Excellent option: Provides endometrial protection + contraception + treats heavy menstrual bleeding.
   • Licensed for 5 years as HRT progesterone component.
   • Minimal systemic absorption.

Avoid older progestogens (norethisterone, medroxyprogesterone acetate) if possible - higher breast cancer risk signal. [15]

3. Preparations (Examples UK)

Oestrogen-Only (for women post-hysterectomy):

• Patches: Evorel 50, Estradot 50.
• Gel: Oestrogel (2-4 pumps), Sandrena (1 mg).
• Oral: Estradiol valerate 2 mg.

Sequential Combined (for perimenopause, LMP less than 12 months):

• Evorel Sequi (patch): Estradiol + norethisterone (cyclical).
• Femoston 1/10 (oral): Estradiol + dydrogesterone (14 days).
• Utrogestan 200 mg (days 1-14) + separate oestrogen patch/gel.

Continuous Combined (for postmenopause, LMP >12 months):

• Evorel Conti (patch): Estradiol + norethisterone (daily).
• Femoston Conti (oral): Estradiol + dydrogesterone (daily).
• Kliofem, Kliovance (oral): Estradiol + norethisterone (daily).
• Utrogestan 100 mg daily + separate oestrogen patch/gel.

IUS + Oestrogen:

• Mirena IUS + Oestrogel/patch (any dose).

4. Testosterone Therapy (for Hypoactive Sexual Desire Disorder)

• Consider if low libido persists despite adequate HRT.
• Testosterone gel (unlicensed in UK for women; use male preparation at lower dose, e.g., Testogel 1/10th sachet).
• Monitor levels (aim for upper female reference range).
• Side effects: Acne, hirsutism, voice deepening (rare at physiological doses). [16]

5. Tibolone

• Synthetic steroid with oestrogenic, progestogenic, androgenic activity.
• Single daily tablet (2.5 mg).
• No withdrawal bleed (oestrogenic on bone/VMS; progestogenic on endometrium).
• Use if: >12 months amenorrhoea, prefer single tablet.
• Higher stroke risk than standard HRT; avoid if vascular risk factors. [17]

---

C. Local (Vaginal) Oestrogen

Indications:

• Genitourinary Syndrome of Menopause (GSM). [8]
• Can be used alone or WITH systemic HRT (systemic HRT often insufficient for GSM).

Preparations:

• Estradiol pessaries: Vagifem 10 mcg (daily for 2 weeks, then twice weekly).
• Estriol cream: Ovestin 0.1% (nightly for 2 weeks, then twice weekly).
• Estradiol ring: Estring 7.5 mcg/day (replaced every 3 months).

Safety:

• Minimal systemic absorption.
• Does NOT require progesterone (endometrial safety data excellent).
• Safe in breast cancer survivors (discuss with oncology team). [8]
• Safe long-term (no arbitrary time limit).

---

D. Management of Premature Ovarian Insufficiency (POI)

Key Principles:

1. HRT is MANDATORY until at least age 51 (natural menopause age) - NOT optional. [4,5]
   • Prevents: Osteoporosis, cardiovascular disease, cognitive decline, premature mortality.
   • Higher doses often required than standard HRT (e.g., estradiol 100 mcg patch).
2. Contraception: Fertility is very low but NOT zero (5-10% conceive spontaneously). COCP or IUS recommended.
3. Psychological support: Diagnosis is devastating (fertility loss, premature aging).
4. Investigations: Identify cause (genetic, autoimmune, iatrogenic).
5. Fertility counseling: Egg donation is primary option.
6. Long-term monitoring: Bone density, cardiovascular risk, mental health.

POI HRT Regimen Examples:

• Estradiol 100 mcg patch + Utrogestan 200 mg (days 1-14) OR Mirena IUS.
• COCP (contains higher oestrogen doses than HRT - acceptable alternative in young women).

---

E. Duration of HRT

No Arbitrary Time Limit. [1,2,12]

• Previous guidance recommending 5-year limit was based on misinterpretation of WHI study.
• Continue as long as benefits outweigh risks (individualized decision).
• Annual review: Symptoms, satisfaction, side effects, risk factors, breast screening up-to-date.
• Many women continue HRT long-term (>10 years) safely.

Stopping HRT:

• Gradual tapering vs abrupt cessation (no evidence for superiority of either).
• ~50% experience symptom recurrence if stopped.
• Can restart if symptoms return.

---

9. Complications and Risks of HRT

The Context: WHI Study and Its Legacy

The 2002 Women's Health Initiative (WHI) study caused global panic and HRT cessation. Key flaws:

• Used conjugated equine oestrogens (CEE) + medroxyprogesterone acetate (MPA) - NOT modern body-identical HRT.
• Studied older women (average age 63) - started HRT >10 years post-menopause.
• Oral route only (increases VTE risk). [18]

Modern Evidence:

Body-identical HRT (estradiol + micronised progesterone) via transdermal route in women less than 60 years has a FAVOURABLE risk-benefit profile. [14,15]

---

Breast Cancer

Absolute Risk:

• Oestrogen-only HRT: Little to no increased risk (may even be protective). [14]
• Combined HRT (oestrogen + progestogen):
  • 4 additional cases per 1,000 women over 5 years. [15]
  • Risk lower with micronised progesterone vs synthetic progestogens.
  • Risk falls after stopping HRT.

Context:

• Obesity causes ~6 additional cases per 1,000 women.
• 2 units alcohol daily causes ~5 additional cases per 1,000 women.
• HRT risk is SMALLER than lifestyle risks.

Risk Reduction:

• Use body-identical hormones (estradiol + micronised progesterone).
• Transdermal route.
• Maintain healthy weight, limit alcohol.

Contraindications:

• Current breast cancer.
• Recent breast cancer (less than 5 years - individualized discussion with oncology).

---

Venous Thromboembolism (VTE)

Oral HRT:

• Increases VTE risk 2-3 fold (absolute risk: 2-3 additional cases per 1,000 women per year). [19]
• Risk highest in first year.

Transdermal HRT:

• NO increased VTE risk. [19]
• Mechanism: Avoids hepatic first-pass metabolism → no procoagulant effect.

Absolute Contraindications:

• Current VTE.
• Active thrombophilia (if HRT essential, use transdermal + consider thromboprophylaxis).

Strong Contraindications (use transdermal only if HRT essential):

• Previous VTE.
• Known thrombophilia.
• Active cancer.
• BMI >40.

---

Cardiovascular Disease (CVD) and Stroke

Timing Hypothesis: [10,14]

• HRT started early (less than 60 years, less than 10 years post-menopause): Neutral or protective for CVD; neutral stroke risk.
• HRT started late (>60 years, >10 years post-menopause): Small increased stroke/CVD risk.

Mechanism:

• Early HRT prevents atherosclerosis progression.
• Late HRT may destabilize existing plaques.

Practical Guidance:

• HRT is safe for primary prevention in women less than 60 years.
• Avoid HRT initiation >60 years unless compelling symptoms (not for CVD prevention).
• Transdermal route preferred (lower stroke risk than oral).

Contraindications:

• Recent MI/stroke (less than 6-12 months).
• Uncontrolled hypertension.
• Active angina.

---

Endometrial Cancer

Risk with Unopposed Oestrogen:

• Women with a uterus on oestrogen-only HRT have 4-10 fold increased risk of endometrial hyperplasia/cancer. [1]

Risk with Combined HRT:

• Adequate progesterone (≥12 days/month) eliminates excess risk.
• Continuous combined HRT: Endometrial cancer risk is LOWER than untreated women (protective). [1]

Golden Rule:

• Never give unopposed oestrogen to a woman with a uterus (except if using Mirena IUS as progesterone component).

---

Other Risks

Ovarian Cancer:

• Small increased risk (1 additional case per 1,000 women over 5 years).
• Falls after stopping.

Gallbladder Disease:

• Oral HRT increases risk (transdermal does not).

Dementia:

• WHI Memory Study: HRT started >65 years increased dementia risk.
• HRT started less than 60 years: No increased risk; possible protective effect (controversial). [11]

---

10. Prognosis and Outcomes

Symptom Natural History

• Vasomotor symptoms: Median duration 7.4 years (range: 1-20+ years). [7]
• 10% of women experience symptoms for >20 years.
• African-American and Hispanic women have longer duration than Caucasian/Asian women.

With HRT Treatment

• Vasomotor symptoms: 80-90% reduction in frequency/severity. [14]
• Quality of life: Significant improvement (sleep, mood, sexual function, work productivity).
• Bone density: HRT prevents bone loss; reduces fracture risk by ~40%. [9]
• GSM: Local oestrogen is highly effective (>90% improvement).

Long-Term Health Outcomes

Untreated Menopause:

• Accelerated bone loss → osteoporosis → fractures.
• Increased cardiovascular disease risk (2-5 years post-menopause).
• Persistent GSM (progressive, does not resolve).
• Reduced quality of life.

HRT Use (started less than 60 years, used 5-10+ years):

• Reduced all-cause mortality (10-20% reduction in observational studies). [14]
• Reduced fracture risk.
• Improved quality of life.
• Small increased breast cancer risk (offset by benefits in most women).

---

11. Special Situations

Hysterectomy (No Uterus)

• Oestrogen-only HRT (no progesterone required).
• Lower breast cancer risk than combined HRT.
• Simpler regimen.

Migraine

• Hormonal fluctuations can trigger migraine.
• Transdermal HRT preferred (stable hormone levels).
• Avoid sequential HRT if migraine worsens during progesterone phase (use continuous combined or Mirena IUS).
• Migraine with aura: Transdermal ONLY (oral HRT increases stroke risk).

History of Endometriosis/Adenomyosis

• Post-hysterectomy + bilateral salpingo-oophorectomy: Consider adding progesterone to oestrogen HRT (prevent reactivation of residual endometriosis).

Previous Gynaecological Cancer

• Endometrial cancer (early stage, treated): HRT generally contraindicated; consider if severe symptoms, discuss with oncology.
• Ovarian cancer (epithelial, treated): HRT usually acceptable.
• Cervical cancer: HRT acceptable.

Breast Cancer Survivors

• HRT generally avoided.
• Alternatives: SSRIs, gabapentin, CBT for VMS; local vaginal oestrogen for GSM (safe). [8]
• If severe, treatment-refractory symptoms: Individualized discussion with oncology (some women with ER-negative tumors may be candidates).

---

12. Quality of Life and Patient-Centered Care

Shared Decision-Making

HRT decisions must be individualized:

• Symptom severity (impact on work, relationships, sleep, mental health).
• Risk factors (personal/family history breast cancer, VTE, CVD).
• Patient preferences (route, regimen, bleeding patterns).
• Contraindications (absolute vs relative).

Menopause in the Workplace

• 75% of women experience symptoms that impact work performance. [20]
• Employers should provide: Flexible working, temperature control, access to cold water, menopause policies.
• Menopause is NOT a disease but symptoms can be disabling.

Cultural and Socioeconomic Factors

• Menopause remains taboo in many cultures.
• Lower socioeconomic groups have poorer access to HRT, specialist care.
• Education critical: Many women (and healthcare professionals) lack accurate knowledge due to WHI legacy.

---

13. Emerging Therapies and Future Directions

Neurokinin-3 (NK3) Receptor Antagonists

• Fezolinetant: Oral non-hormonal treatment targeting thermoregulatory center.
• Phase III trials show 60% reduction in VMS frequency/severity.
• Licensed in USA (2023); awaiting UK approval.
• Alternative for women who cannot/will not use HRT. [21]

Selective Estrogen Receptor Modulators (SERMs)

• Raloxifene: Prevents bone loss, reduces breast cancer risk; NO effect on VMS (may worsen).
• Bazedoxifene + CEE (Duavee): Tissue-selective; avoid in UK (oral CEE, not body-identical).

Personalized HRT

• Genetic testing (CYP450 polymorphisms, BRCA status) may guide individualized regimens.
• Current evidence insufficient for routine use.

---

14. Guidelines and Evidence Summary

Key Guidelines

• NICE NG23 (2015): Menopause: diagnosis and management. [12]
• British Menopause Society (BMS): Consensus statements on HRT, POI, GSM. [1,22]
• North American Menopause Society (NAMS): Hormone therapy position statement. [14]
• European Menopause and Andropause Society (EMAS): Guidelines on HRT.
• International Menopause Society (IMS): Global consensus on HRT.

Evidence Levels

---

15. Red Flags - When to Refer/Investigate Urgently

1. Postmenopausal bleeding (PMB): Urgent 2-week-wait referral (exclude endometrial cancer).
2. Unilateral leg swelling on HRT: Exclude VTE (stop HRT, anticoagulation if confirmed).
3. New severe headache/visual disturbance: Exclude intracranial pathology (stop HRT if migraine with aura/stroke suspected).
4. Severe depression/suicidal ideation: Urgent mental health referral.
5. Unexplained bone pain: Exclude osteoporosis with fracture, metastatic disease (DEXA, imaging).
6. Breast lump: Urgent 2-week-wait referral.
7. Very young age (less than 30 years POI): Genetic/autoimmune causes (karyotype, FMR1, autoimmune screen).

---

16. Exam Pearls (MRCOG, FRANZCOG, MRCP)

High-Yield Facts

1. Diagnosis of menopause is CLINICAL in women >45 years - do NOT check FSH.
2. Sequential HRT (withdrawal bleed) if LMP less than 12 months; Continuous HRT (amenorrhoea) if LMP >12 months.
3. Transdermal HRT has NO increased VTE risk vs oral HRT (2-3 fold increase).
4. Micronised progesterone has lower breast cancer risk than synthetic progestogens.
5. POI requires HRT until age 51 (NOT optional) - prevent CVD, osteoporosis, mortality.
6. Local vaginal oestrogen is SAFE in breast cancer survivors (minimal systemic absorption).
7. Timing hypothesis: HRT started less than 60 years is cardioprotective; started >60 years may increase CVD/stroke risk.
8. Absolute breast cancer risk: 4 extra cases/1000 women over 5 years with combined HRT (less than obesity/alcohol).
9. Postmenopausal bleeding is endometrial cancer until proven otherwise (2-week-wait referral).
10. GSM is progressive and does NOT spontaneously resolve - requires treatment.

OSCE Stations

HRT Counselling:

• Assess symptoms, menstrual status, contraindications.
• Explain regimen choice (sequential/continuous, oral/transdermal).
• Discuss risks (breast cancer, VTE) in context (compare to lifestyle risks).
• Explain benefits (symptom relief, bone protection, QOL).
• Address media misconceptions (WHI study).

POI Diagnosis:

• Empathetic breaking of bad news.
• Explain need for lifelong HRT, fertility implications, investigations required.

PMB Investigation:

• Urgent referral, transvaginal ultrasound, hysteroscopy + biopsy.

---

17. Patient and Layperson Explanation

Do I need hormone therapy?

If your symptoms (hot flushes, brain fog, poor sleep, vaginal dryness) are affecting your quality of life, HRT is the most effective treatment. It is very safe for most women under 60 years.

What about the cancer risk?

The media scared many women in the early 2000s. The truth is:

• The risk of breast cancer is very small (4 extra cases per 1,000 women over 5 years).
• This is less than the risk of being overweight or drinking 2 glasses of wine a night.
• If you don't have a womb, the risk is almost zero.
• Oestrogen-only HRT (for women without a uterus) does NOT increase breast cancer risk.

Will I gain weight?

There is no evidence HRT causes weight gain. Menopause itself slows metabolism, so weight gain happens anyway, but HRT doesn't add to it. Some women find HRT helps them maintain weight because they sleep better and have more energy to exercise.

Which type should I take?

• Patches/Gel (Transdermal): Safest option (no risk of blood clots). Applied to skin.
• Tablets (Oral): Convenient but small clot risk (use only if normal weight, no risk factors).
• Mirena Coil (IUS): Great if you also need contraception or have heavy periods. Provides progesterone component of HRT.

Can I take it forever?

There is no arbitrary time limit. You can take HRT as long as the benefits outweigh the risks for you. Many women take it for 10-20+ years safely. You should review annually with your doctor.

What if I can't take HRT?

Alternatives include:

• Antidepressants (venlafaxine, citalopram) - reduce hot flushes by ~50%.
• Gabapentin - helps with hot flushes and sleep.
• CBT - psychological therapy that helps you cope with symptoms.
• Vaginal oestrogen cream/pessaries - safe for everyone, treats dryness.

When should I see a doctor urgently?

• Any bleeding after your periods have stopped for >12 months.
• Severe leg swelling (especially one leg).
• Severe headaches or visual changes.
• Breast lump.

---

18. Viva Questions and Model Answers

Q1: A 48-year-old woman has been on continuous combined HRT for 2 years. She now has irregular bleeding. What is your approach?

Model Answer:

"This is unscheduled bleeding on continuous combined HRT - a red flag that requires investigation to exclude endometrial pathology.

Initial Management:

1. Review her HRT regimen: Was she truly postmenopausal when started (LMP >12 months)? If not, continuous HRT may cause breakthrough bleeding due to endogenous hormones.
2. Check compliance: Missing pills can cause bleeding.
3. Examine: Any other sources (cervical, vulval)?

Investigations:

• Transvaginal ultrasound: Endometrial thickness (>4 mm requires biopsy).
• Endometrial biopsy (Pipelle or hysteroscopy): Exclude hyperplasia, cancer, polyps.

Possible Causes:

• Endometrial atrophy (most common - benign).
• Inadequate progestogen (switch to higher dose or different type).
• Endometrial polyp.
• Endometrial hyperplasia/cancer (rare but must exclude).

Outcome:

• If investigations normal: Reassure, optimize HRT regimen (may need sequential if persistent bleeding).
• If hyperplasia: Stop HRT, treat with progestogens, repeat biopsy.
• If cancer: Urgent referral to gynaecological oncology."

---

Q2: Explain the timing hypothesis in relation to HRT and cardiovascular disease.

Model Answer:

"The timing hypothesis proposes that the cardiovascular effects of HRT depend on the timing of initiation relative to menopause. [10,14]

Early HRT (less than 60 years, less than 10 years post-menopause):

• Oestrogen has favourable effects on endothelial function, lipid profile, and vascular tone.
• Prevents atherosclerosis progression.
• Observational studies show reduced CVD and all-cause mortality.
• WHI oestrogen-only arm (younger women) showed reduced coronary events.

Late HRT (>60 years, >10 years post-menopause):

• Atherosclerosis is already established.
• Oestrogen may destabilize existing plaques → plaque rupture, thrombosis.
• WHI study (average age 63) showed small increased CVD/stroke risk.

Mechanism:

• Early: Vasculoprotective (NO production, anti-inflammatory).
• Late: Prothrombotic (procoagulant effects dominate).

Clinical Implication:

• HRT is safe and potentially cardioprotective in women less than 60 years.
• Avoid initiating HRT >60 years for CVD prevention (use statins instead).
• If HRT is essential for symptoms >60 years, use transdermal route (lower stroke risk)."

---

Q3: A 35-year-old woman is diagnosed with POI. How do you counsel her?

Model Answer:

"This is a devastating diagnosis - she is grieving the loss of fertility and facing premature aging. Empathy is critical.

Explanation:

• 'Your ovaries have stopped working earlier than expected. This means your periods will stop and you will go through menopause now instead of in your 50s.'
• 'I understand this is shocking news. It is normal to feel upset, angry, or confused.'

Immediate Management:

1. HRT is essential (NOT optional):
   • 'You need hormone replacement therapy to protect your heart, bones, and brain.'
   • 'You will need to take HRT until at least age 51 (the natural menopause age), possibly longer.'
   • Higher doses than standard HRT (e.g., 100 mcg patch).
2. Contraception:
   • 'Although fertility is very low, pregnancy is still possible (5-10% chance).'
   • 'The combined oral contraceptive pill or Mirena coil is recommended.'
3. Investigations (identify cause):
   • Blood tests: Karyotype (Turner syndrome), FMR1 gene (Fragile X), autoimmune screen (Addison's, thyroid).
   • Pelvic ultrasound.

Fertility:

• 'Natural conception is very unlikely but not impossible - some women do ovulate occasionally.'
• 'Egg donation is the most successful fertility treatment (50-60% live birth rate per cycle).'
• 'I will refer you to a fertility specialist to discuss options.'

Psychological Support:

• 'This is a huge emotional blow. I will refer you to a psychologist/support group (Daisy Network).'
• 'Many women with POI go on to have families through egg donation and live healthy lives on HRT.'

Follow-Up:

• Bone density scan (DEXA).
• Annual reviews: Symptoms, HRT optimization, mental health, cardiovascular risk.

Key Message:

• 'With HRT and support, you can lead a normal, healthy life. I am here to help you through this.'"

---

19. References

1. Hamoda H. Premature ovarian insufficiency, early menopause, and induced menopause. Best Pract Res Clin Endocrinol Metab. 2024;38(1):101823. doi:10.1016/j.beem.2023.101823

2. Santoro N, et al. The Menopause Transition: Signs, Symptoms, and Management Options. J Clin Endocrinol Metab. 2021;106(1):1-15. doi:10.1210/clinem/dgaa764

3. Duralde ER, et al. Management of perimenopausal and menopausal symptoms. BMJ. 2023;382:e072612. doi:10.1136/bmj-2022-072612

4. Nash Z, et al. Premature ovarian insufficiency. BMJ. 2024;384:e077469. doi:10.1136/bmj-2023-077469

5. Li M, et al. The global prevalence of premature ovarian insufficiency: a systematic review and meta-analysis. Climacteric. 2023;26(2):95-102. doi:10.1080/13697137.2022.2153033

6. Zhu D, et al. Body mass index and age at natural menopause: an international pooled analysis of 11 prospective studies. Eur J Epidemiol. 2018;33(8):699-710. doi:10.1007/s10654-018-0367-y

7. Avis NE, et al. Duration of menopausal vasomotor symptoms over the menopause transition. JAMA Intern Med. 2015;175(4):531-539. doi:10.1001/jamainternmed.2014.8063

8. The NAMS 2020 GSM Position Statement Editorial Panel. The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society. Menopause. 2020;27(9):976-992. doi:10.1097/GME.0000000000001609

9. Eastell R, et al. Postmenopausal osteoporosis. Nat Rev Dis Primers. 2016;2:16069. doi:10.1038/nrdp.2016.69

10. Uddenberg ER, et al. Menopause transition and cardiovascular disease risk. Maturitas. 2024;185:107974. doi:10.1016/j.maturitas.2024.107974

11. Andy C, et al. Systematic review and meta-analysis of the effects of menopause hormone therapy on cognition. Front Endocrinol (Lausanne). 2024;15:1350318. doi:10.3389/fendo.2024.1350318

12. Lumsden MA, et al. The NICE Guideline - Menopause: diagnosis and management. Climacteric. 2016;19(5):426-429. doi:10.1080/13697137.2016.1222483

13. Hunter MS, et al. Cognitive behaviour therapy for menopausal symptoms. Maturitas. 2021;152:42-47. doi:10.1016/j.maturitas.2021.06.015

14. Flores VA, et al. Hormone Therapy in Menopause: Concepts, Controversies, and Approach to Treatment. Endocr Rev. 2021;42(6):720-752. doi:10.1210/endrev/bnab011

15. Collaborative Group on Hormonal Factors in Breast Cancer. Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence. Lancet. 2019;394(10204):1159-1168. doi:10.1016/S0140-6736(19)31709-X

16. Davis SR, et al. Global Consensus Position Statement on the Use of Testosterone Therapy for Women. J Clin Endocrinol Metab. 2019;104(10):4660-4666. doi:10.1210/jc.2019-01603

17. Formoso G, et al. Short and long term effects of tibolone in postmenopausal women. Cochrane Database Syst Rev. 2016;10:CD008536. doi:10.1002/14651858.CD008536.pub3

18. Rossouw JE, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA. 2002;288(3):321-333. doi:10.1001/jama.288.3.321

19. Vinogradova Y, et al. Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases. BMJ. 2019;364:k4810. doi:10.1136/bmj.k4810

20. Griffiths A, et al. The impact of work on the menopause transition. Maturitas. 2013;76(2):142-147. doi:10.1016/j.maturitas.2013.07.005

21. Prague JK, et al. Neurokinin 3 receptor antagonism as a novel treatment for menopausal hot flushes: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet. 2017;389(10081):1809-1820. doi:10.1016/S0140-6736(17)30823-1

22. British Menopause Society. BMS & WHC's 2020 recommendations on hormone replacement therapy in menopausal women. Post Reprod Health. 2020;26(4):181-209. doi:10.1177/2053369120957514

23. Christmas MM, et al. Menopause hormone therapy and urinary symptoms: a systematic review. Menopause. 2023;30(6):681-697. doi:10.1097/GME.0000000000002187

24. Cox S, et al. Genitourinary Syndrome of Menopause. Med Clin North Am. 2023;107(2):357-373. doi:10.1016/j.mcna.2022.10.017